Search
ALT-2074
go.drugbank.com/drugs/DB05631InvestigationalAn organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. … BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.
Stanozolol
go.drugbank.com/drugs/DB06718ApprovedVet approvedStanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes.
Categories: Anabolic Agents for Systemic UsePimecrolimus
go.drugbank.com/drugs/DB00337ApprovedInvestigationalPimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007. It is currently available as a topic cream used in the treatment of ato...
Categories: Agents for Dermatitis, Excluding CorticosteroidsFenproporex
go.drugbank.com/drugs/DB01550ApprovedIllicitWithdrawnIt is used as an appetite suppressant and a treatment for obesity. … The N-2-cyanoethyl substituent was once believed to be resistant to cleavage, because fenproporex -- once recommended as an obesity treatment for patients with cardiovascular disease -- was originally
REC-994
go.drugbank.com/drugs/DB15616InvestigationalREC-994 was cleared by the FDA in July, 2018 for a phase I trial for the treatment of cerebral cavernous malformation (CCM).
Octyl triazone
go.drugbank.com/drugs/DB15469InvestigationalMixtures: Kiehls Activated Sun Protector Sunscreen SPF 50 For Face and Body For All Skin Types, Kiehls Activated Sun Protector Sunscreen SPF 30 For Face and Body For All Skin TypesFK352B
go.drugbank.com/drugs/DB06484ExperimentalFK352B is a adenosine A1 antagonist that is developed for the treatment of dialysis-induced hypotension.
Amibegron
go.drugbank.com/drugs/DB05395InvestigationalAmibegron is an agonist for atypical beta3-adrenoceptors which inhibits intestinal motility.
Zuranolone
go.drugbank.com/drugs/DB15490ApprovedInvestigational[A260791] Zuranolone was approved by the FDA on August 4th, 2023, and it is currently the only approved treatment for women with postpartum depression.